Jubilant Pharmova Ltd - JUBILANT PHARMO Share Price

Sector: Pharmaceuticals | ISIN: INE700A01033
₹ 717.80 (1.14%) icon23 May, 2024, 12:00:00 AM
Open
₹ 709.70
Prev. Close
₹ 709.70
Turnover(lac)
₹ 0.00
Day's High
₹ 722.00
Day's Low
₹ 701.00
52 Wk High
₹ 741.00
52 Wk Low
₹ 318.75
Book Value
₹ 151.52
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 11,434.55
P/E
0.00
EPS
0.00
Div. Yield
0.70

Jubilant Pharmova Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/23/2024 12:00:00 AM

    ₹ 717.8 8.10 1.14
  • Open
  • ₹ 709.7
  • Prev. Close
  • ₹ 709.7
  • Turnover(Lac.)
  • ₹ 1,266
  • Day's High
  • ₹ 722
  • Day's Low
  • ₹ 701
  • 52 Week's High
  • ₹ 741
  • 52 Week's Low
  • ₹ 318.75
  • Book Value
  • ₹ 151.52
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 11,434.55
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0.7

Jubilant Pharmova Ltd Corporate Actions

26 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Jan , 2024

12:00 AM

19 Oct , 2023

12:00 AM

19 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

07 Aug , 2023

12:00 AM

AGM

Announcement date: 07 Aug , 2023

View Details

29 May , 2023

12:00 AM

Dividend

Dividend amount: 5
Announcement date: 29 May , 2023

View Details

26 Jun , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Jun , 2023

12:00 AM

21 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

No Record Found


Jubilant Pharmova Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Jubilant Pharmova Ltd SHAREHOLDING SNAPSHOT
23 May , 2024 | 09:24 PM

PROMOTER - TOTAL50.68%

Indian: 47.39%

Foreign: 3.2869%

NON-PROMOTER - TOTAL 48.74%

Institutions: 22.84%

Non-Institutions: 25.90%

CUSTODIES - 0.58%

Custodies: 0.58%

See More Details
ad IconAd Image

Jubilant Pharmova Ltd FINANCIALS

View Profit & Loss Graph

Jubilant Pharmova Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Jubilant Pharmova Ltd

  • Shyam S Bhartia
  • Chairman (Non-Executive)
  • Hari S Bhartia
  • Co-Chairman & Non-Exe.Director
  • S Sridhar
  • Non-Exec. & Independent Dir.
  • Sudha Pillai
  • Non-Exec. & Independent Dir.
  • Ashok Misra
  • Non-Exec. & Independent Dir.
  • Vivek Mehra
  • Non-Exec. & Independent Dir.
  • SUSHIL KUMAR ROONGTA
  • Non-Exec. & Independent Dir.
  • Priyavrat Bhartia
  • Managing Director
  • Arjun Shanker Bhartia
  • Joint Managing Director
  • Arun Seth
  • Non-Exec. & Independent Dir.
  • Arvind Chokhany
  • Whole Time Director & CFO
  • Naresh Kapoor
  • Company Sec. & Compli. Officer
  • R Kumar
  • Whole Time Director
  • Shirish Gundopant Belapure
  • Independent Director

Summary

Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs. The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions. . Proprietary novel drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases. The Company was incorporated in 21st June, 1978. The Company tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983, the companys commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JLSL had... Read More


Reports by Jubilant Pharmova Ltd


Reports by Jubilant Pharmova Ltd

Company FAQ

No Record Found